February 7, 2025 02:42 PM EST

Major FDA staff cuts would slow drug reviews, experts say

Zachary Brennan

Senior Editor

The Trump administration’s reported plans to potentially lay off thousands of FDA employees could slow the agency’s reviews of new drugs, experts say, in addition …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Major FDA staff cuts would slow drug reviews, experts say

Zachary Brennan

Senior Editor

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

FDA rejects Stealth's rare disease drug, but offers potential for accelerated approval

Updated: Trump administration halts more than $750M in funds for Moderna’s bird flu vaccine

PepGen ditches Duchenne programs after mid-stage fail, switches to previously halted muscle wasting therapy

Oric locks down cash for Phase 3 prostate cancer trial with early data in hand

Exclusive: Movement disorder biotech Vima steps onto scene with $60M

From weeks to days: how Aizon Intelligent Agents transform pharma validation

Ma­jor FDA staff cuts would slow drug re­views, ex­perts say

Senior Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Major FDA staff cuts would slow drug reviews, experts say